At Felicitex we are targeting the unique mechanism of cancer survival and acquired resistance: sleeping niche. By depriving cancer cells from "sleep" and, therefore, exhausting them we program them to become vulnerable and sensitive to treatments.

We have three clinical drug candidates ready for IND enabling studies.